A Novel Convergent Synthesis of the Potent Antiglaucoma Agent Tafluprost
Tafluprost (AFP-168, 5) is a unique 15-deoxy-15,15-difluoro-16-phenoxy prostaglandin F2α (PGF2α) analog used as an efficacious ocular hypotensive agent in the treatment of glaucoma and ocular hypertension, as monotherapy, or as adjunctive therapy to β-blockers. A novel convergent synthesis of 5 was...
Main Authors: | Małgorzata Krupa, Michał Chodyński, Anna Ostaszewska, Piotr Cmoch, Iwona Dams |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2017-01-01
|
Series: | Molecules |
Subjects: | |
Online Access: | http://www.mdpi.com/1420-3049/22/2/217 |
Similar Items
-
Application of the Solid-Phase Julia–Lythgoe Olefination in Vitamin D Side-Chain Construction
by: Pierre J. De Clercq, et al.
Published: (2006-08-01) -
Synthesis of prostaglandins and novel N-oxyamide linked oligosaccharide and oligonucleotide mimetics
by: Gong, Yanchun
Published: (2012) -
Long-Term Effectiveness and Safety of Tafluprost, Travoprost, and Latanoprost in Korean Patients with Primary Open-Angle Glaucoma or Normal-Tension Glaucoma: A Multicenter Retrospective Cohort Study (LOTUS Study)
by: Joon-Mo Kim, et al.
Published: (2021-06-01) -
Comparison of the Safety and Efficacy between Preserved and Preservative-Free Latanoprost and Preservative-Free Tafluprost
by: Joon Mo Kim, et al.
Published: (2021-05-01) -
Efficacy and tolerability of preservative-free 0.0015% tafluprost in glaucoma patients: a prospective crossover study
by: Wonseok Lee, et al.
Published: (2017-04-01)